Trading Session Radar Attractors Vitamin Shoppe (VSI), Fabrinet

Vitamin Shoppe, Inc. (NYSE:VSI)

VSI stock surged after the company reported its financial results and delivered its 32nd consecutive quarter of positive comparable retail store sales growth and experienced improving traffic trends throughout the quarter.

For the third quarter 2013, VSI posted total net sales of $272.5 million, an increase of 14.0% year over year, gross profit increased $10.6 million, or 12.8%, to $93.1 million, compared with the same period the prior year, and income from operations of $26.1 million, an increase of 5.4% from third quarter 2012.

VSI is a leading multi-channel specialty retailer of nutritional products based in North Bergen, New Jersey. In its stores and on its website, VSI carries one of the most comprehensive retail assortments in the industry, including vitamins, minerals, specialty supplements, herbs, sports nutrition, homeopathic remedies, green living products, and beauty aids.

More about Vitamin Shoppe, Inc. (NYSE:VSI) at www.vitaminshoppe.com

**

Fabrinet (NYSE:FN)

Shares of FN increased their price after the company reported another strong quarter of revenue, margin and EPS growth on its financial results.

For the first quarter of fiscal 2014, FN posted total revenue of $171.6 million, an increase of 8.2% year over year, GAAP net income of $19.2 million, or $0.55 per diluted share, compared to $16.0 million, or $0.46 per diluted share in the same period the prior year, and Non-GAAP net income of $14.2 million, or $0.40 per diluted share, an increase of 10.9% compared to $12.8 million, or $0.36 per diluted share, in the first quarter of fiscal 2013.

FN is a leading provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and subsystems, industrial lasers and sensors.

More about Fabrinet (NYSE:FN) at www.fabrinet.com .

**

Cytori Therapeutics, Inc. (Nasdaq:CYTX)

Shares of CYTX skyrocketed on Tuesday's market activity after the company reported a partnership with Lorem Vascular to commercialize its regenerative cell technology for the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia.

Under the agreement, Lorem Vascular committed to pay up to $531 million in license fees, opening product purchase commitments and CYTX equity purchases.

Lorem Vascular will buy 8 million shares of CYTX for $3 per share, investing a total of $24 million in the company, and it will order $7 million in devices and consumable products. The 30-year licensing agreement could bring CYTX as much as $500 million in fees.

Lorem and CYTX have implemented a regulatory plan in China and anticipate approval in 2014.

CYTX is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. CYTX ’s scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive.

More about Cytori Therapeutics, Inc. (Nasdaq:CYTX) at www.cytori.com

**

Recon Technology, Ltd. (Nasdaq:RCON)

Shares of RCON soared after the company reported that it recently received several sales orders for specialized oilfield furnaces from China National Petroleum Company's Jiling Oilfield Company and Huabei Oilfield Company. The total value of these contracts will be approximately RMB11 million or USD1.9 million.

According to sales contracts, RCON will provide 9 vacuum heating furnaces to Jiling Oilfield Company, and 6 phase-change heating furnaces to Huabei Oilfield Company.

RCON provides leading Chinese oil and gas companies with automation services designed to increase efficiency and profitability in relation to the exploration, extraction, production, refining and transportation of field based petroleum products.

More about Recon Technology, Ltd. (Nasdaq:RCON) at www.recon.cn .

**

Read full disclaimer at www.mikezaman.com/disclaimer